LOSARTAN POTASSIUM MARKET
INTRODUCTION
Angiotensin II receptor blockers are a class of medications that includes losartan potassium. (ARBs). It helps to prevent kidney damage brought on by diabetes and is used to treat high blood pressure (hypertension).
Angiotensin II, a hormone that tightens blood vessels and elevates blood pressure, is blocked by losartan in order to work. Losartan aids in dilating blood vessels and lowering blood pressure by preventing the action of angiotensin II.
With or without food, losartan potassium is typically taken orally once per day. Depending on the patient’s medical condition and reaction to treatment, the medication’s dosage and frequency may change.
Losartan potassium side effects can include headache, fatigue, diarrhea, and dizziness, just as with other medicine.
More severe side effects include low blood pressure, allergic reactions, and liver issues can occasionally result from it. Before using losartan potassium, it’s crucial to talk to your doctor, especially if you have a history of liver or kidney issues, are pregnant, or are nursing a baby.
LOSARTAN POTASSIUM MARKET SIZE AND FORECAST
Global losartan potassium market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
LOSARTAN POTASSIUM MARKET COVID-19 IMPACT
Losartan potassium has being investigated as a potential COVID-19 therapy. In hospitalized patients with COVID-19 and acute lung injury, a randomized clinical trial involving 205 patients indicated that maximal dose losartan did not reduce lung injury at 7 days.
By decreasing the function of epithelial sodium channels (ENaC), SARS-CoV-2 may disrupt potassium balance, according to another study Losartan was tested in a clinical trial to see if it worked for COVID-19 patients who needed to be hospitalized.
Losartan may lessen the activity of the renin-angiotensin system, which is overactive in persons with high blood pressure and may raise their chance of having lung issues from COVID-19. Losartan does not stop the virus that causes COVID-19.
The clinical symptoms of COVID-19 have frequently been described as electrolyte problems, particularly potassium abnormalities.
However, there is no proof that losartan has any impact on COVID-19 patients’ potassium levels. Losartan’s effectiveness for COVID-19 patients who needed to be hospitalized was examined in a clinical trial The purpose of the research was to see if losartan may lessen the requirement for hospitalization, supplemental oxygen use, or mechanical breathing in COVID-19 patients. The experiment ended on February.
LOSARTAN POTASSIUM MARKET COMPANY PROFILE
- Merck & Co., Inc
- Alembic Pharmaceuticals Limited
- Torrent Pharmaceuticals Limited
- Aurobindo Pharma Limited
- Zydus Cadila
THIS LOSARTAN POTASSIUM MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS
- How many losartan potassium are manufactured per annum globally? Who are the sub-component suppliers in different regions?
- Cost breakup of a Global losartan potassium and key vendor selection criteria
- Where is the losartan potassium manufactured? What is the average margin per unit?
- Market share of Global losartan potassium market manufacturers and their upcoming products
- Cost advantage for OEMs who manufacture Global losartan potassium in-house
- key predictions for next 5 years in Global losartan potassium market
- Average B-2-B losartan potassium market price in all segments
- Latest trends in losartan potassium market, by every market segment
- The market size (both volume and value) of the losartan potassium market in 2024-2030 and every year in between?
- Production breakup of losartan potassium market, by suppliers and their OEM relationship
